4.7 Article

Pharmacokinetics, mass balance, and metabolism of [14C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension

Journal

ACTA PHARMACOLOGICA SINICA
Volume 44, Issue 1, Pages 221-233

Publisher

NATURE PUBL GROUP
DOI: 10.1038/s41401-022-00922-6

Keywords

TPN171; [C-14]TPN171; PDE5 inhibitor; pulmonary arterial hypertension; healthy volunteers; pharmacokinetics; metabolite identification; mass balance

Ask authors/readers for more resources

TPN171 is a PDE5 inhibitor being tested for the treatment of PAH and ED in China. This study investigated its metabolic mechanism, pharmacokinetics, and clearance pathways in healthy Chinese male volunteers. TPN171 was rapidly absorbed, had a long half-life, and underwent extensive metabolism, primarily catalyzed by CYP3A4. One of its metabolites, a glucuronide metabolite of the O-dealkylated form, was found to be a significant component in human plasma.
TPN171 is a novel phosphodiesterase-5 (PDE5) inhibitor used to treat pulmonary arterial hypertension (PAH) and erectile dysfunction (ED), which currently is undergoing phase II clinical trials in China. In this single-center, single-dose, nonrandomized, and open design study, radiolabeled [C-14]TPN171 was used to investigate the metabolic mechanism, pharmacokinetic characteristics, and clearance pathways of TPN171 in 6 healthy Chinese male volunteers. Each volunteer was administered a single oral suspension of 10 mg (100 mu Ci) of [C-14]TPN171. We found that TPN171 was absorbed rapidly in humans with a peak time (T-max) of 0.667 h and a half-life (t(1/2)) of approximately 9.89 h in plasma. Excretion of radiopharmaceutical-related components was collected 216 h after administration, accounting for 95.21% of the dose (46.61% in urine and 48.60% in feces). TPN171 underwent extensive metabolism in humans. Twenty-two metabolites were detected in human plasma, urine, and feces using a radioactive detector combined with a high-resolution mass spectrometer. According to radiochromatograms, a glucuronide metabolite of O-dealkylated TPN171 exceeded 10% of the total drug-related components in human plasma. However, according to the Food and Drug Administration (FDA) guidelines, no further tests are needed to evaluate the safety of this metabolite because it is a phase II metabolite, but the compound is still worthy of attention. The main metabolic biotransformation of TPN171 was mono-oxidation (hydroxylation and N-oxidation), dehydrogenation, N-dealkylation, O-dealkylation, amide hydrolysis, glucuronidation, and acetylation. Cytochrome P450 3A4 (CYP3A4) mainly catalyzed the formation of metabolites, and CYP2E1 and CYP2D6 were involved in the oxidative metabolism of TPN171 to a lesser extent. According to the incubation data, M1 was mainly metabolized to M1G by UDP-glucuronosyltransferase 1A9 (UGT1A9), followed by UGT1A7 and UGT1A10.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available